Osteoporosis currently affects 3.8 million people in the UK, particularly impacting older women after menopause

Theramex’s Eladynos (abaloparatide) has been recommended by the National Institute for Health Care and Research (NICE) for treating bone disease after menopause.

More than 14,000 people in the UK seek treatment for osteoporosis after menopause, and these patients will benefit from the drug (if there is a very high risk of fracture) once it becomes available in England on the NHS in three months’ time.

Osteoporosis is a bone disease that affects 3.8 million people in the UK. It develops when bone mineral density and bone mass decrease, or when the quality or structure of bone changes, leading to a decrease in bone strength that can increase the risk of broken bones or fractures.

The disease particularly affects older women after menopause, as oestrogen, the hormone important for maintaining bone density and strength, decreases and bone density reduces, making broken bones more common.

NICE’s decision was based on the debilitating impact of osteoporosis on patients’ day-to-day lives and how it impacts their mental and physical health.

The drug treatment, that provides an alternative for patients who have not responded to or cannot tolerate usual treatment options, increases bone density by stimulating the cells that produce new bone while also reducing the risk of fracture.

This treatment option – a pre-filled pen that is injected into the muscle through the skin – has proven to be both clinically effective and cost-effective.

Source：https://www.theguardian.com/society/article/2024/aug/07/new-drug-that-could-prevent-osteoporosis-approved-for-nhs